

Emmet J Jordan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/385694/publications.pdf>

Version: 2024-02-01

11
papers

3,832
citations

933447

10
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

9141
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
2	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
3	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	7.0	225
4	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	7.0	200
5	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
6	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
7	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	1.9	69
8	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	7.1	44
9	Targeted Therapy in Advanced Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 253-262.	1.8	14
10	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype—Phenotype Features—An Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , 2018, 17, e315-e321.	2.3	13
11	The role of novel biologics in biliary cancers. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 325-339.	2.2	0